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Coxiella burnetii is the etiological agent of Q fever, a disease that is often spread to humans
via inhalational exposure to the bacteria from contaminated agricultural sources. Outbreaks
have been observed all over the world with larger foci generating interest in vaccination
programs, most notably in Australia and the Netherlands. Importantly, exposure rates
among military personnel deployed to the Middle East can be relatively high as measured
by seroconversion to C. burnetii -speciﬁc antibodies. Q fever has been of interest to the
biodefense community over the years due to its low infectious dose and environmental
stability. Recent advances in cell-free growth and genetics of C. burnetii also make this
organism easier to culture and manipulate.While there is a vaccine that is licensed for use
in Australia, the combination of biodefense- and public health-related issues associated
with Q fever warrant the development of a safer and more effective vaccine against this
disease.
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Q FEVER DISEASE
An unknown disease was reported in Queensland, Australia in
1933, termed Query Fever (Q fever) that caused non-descript
symptoms including fever, headache, and general malaise. The
etiological agent, Coxiella burnetii, was described in Davis (1938)
and Waag and Fritz (2012). This gram-negative bacterium is an
obligate, intracellular pathogen, oscillating between an infectious
small cell variant and a replicative large cell variant (McCaul and
Williams, 1981). C. burnetii is a zoonosis, persistingwithin domes-
ticated ungulates, such as cattle, horses, sheep, and goats (Langley
et al., 1988; Laughlin et al., 1991).
Coxiella burnetii exposure results from contaminated animal
byproducts, with human exposure often occurring via inhalation
(Lennette and Welsh, 1951). Infectious particles can travel several
kilometers by wind leading to epidemics (Tissot-Dupont et al.,
2004). Although uncommon relative to inhalational exposure,
transmission of the bacteria can occur by ingestion of unpasteur-
izedmilk andvectors, speciﬁcally ticks (Davis,1938;Huebner et al.,
1948). The minimum inoculum of C. burnetii is estimated to be
1.18 bacteria with an estimated ID50 of 5.58 bacteria, underscoring
the potential of this bacterium to cause a signiﬁcant public health
toll (Brooke et al., 2013).
Many exposed individuals remain asymptomatic, ∼60%; how-
ever, those that develop acute Q fever have no distinguishing
clinical signs or symptoms and generally present with malaise,
fever, headache, chills, and can progress to pneumonia. Acute
hepatitis with an elevation of aspartate transaminase and/or ala-
nine transaminase has also been reported (Palmela et al., 2012).
Acute disease is typically self-limiting with low mortality (Waag
and Fritz, 2012). Contraction of disease during pregnancy, how-
ever, can result in complications such as premature birth, stillbirth,
and lowbirthweight due to bacterial tropism for the placenta (Ellis
et al., 1983; Stein and Raoult, 1998; Jover-Diaz et al., 2001; Langley
et al., 2003). All individuals who have been exposed to C. burnetii
are at risk of developing chronicQ fever (Brooke et al., 2013, 2014),
with an estimated 1–5% progressing to chronic Q fever, placing
them at risk of serious long-term sequelae (Botelho-Nevers et al.,
2007; Million et al., 2010).
Individuals with pre-existing cardiac valvular disease, aortic
aneurysm, vascular grafts, immunocompromised status, andpreg-
nancy at time of exposure are at an increased risk for developing
chronic Q fever (Raoult et al., 2000; Fenollar et al., 2001; Landais
et al., 2007), which most commonly results in endocarditis or
hepatitis (Yebra et al., 1988). Chronic fatigue syndrome is com-
monly observed in the short term following diagnosis (Brooke
et al., 2014). The disability adjusted life years burdens were esti-
mated for both H1N1 inﬂuenza and Q fever during the recent
Netherlands epidemic, with the burden due to chronic Q fever
being estimated at 8–28 times more severe per case compared to
H1N1 inﬂuenza (Brooke et al., 2014). This highlights the need for
better diagnostics and medical countermeasures, particularly in
cases of chronic Q fever.
Q FEVER DIAGNOSTICS AND MEDICAL COUNTERMEASURES
The current standard for Q fever diagnosis is a commercially
available indirect immunoﬂuorescence assay. Cultivation of the
organism is not recommended given its high infectivity and
requirement of Biosafety Level 3 containment. The limited utility
of diagnostic assays for Q fever is exacerbated by the non-speciﬁc
disease symptoms and lack of clinical indicators to suggest Q fever
early in the course of disease. Culture and serum based PCR
are only positive in 50–60% of chronically infected individuals
(Fenollar et al., 2004). Antibody responses to the Phase I andPhase
II antigenic variants allow for the differentiation between acute
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and chronic phases of disease. Phase I C. burnetii possess full-
length lipopolysaccharide (LPS) whereas Phase II variants begin
to appear in the chronic phase with a truncated LPS lacking O
antigen (Schramek and Mayer, 1982; van der Hoek et al., 2012).
PCR-based approaches have been explored given that bacterial
DNA can be detected prior to the antibody response, thereby
curtailing the diagnostic delay. A positive PCR is indicative of
infection, but a negative result is inconclusive (Fournier et al.,
1998). The combination of non-descript symptoms and inef-
ﬁcient assays makes the diagnosis of Q fever a fairly daunting
challenge.
Although acute Q fever is typically self-limiting, a 2 weeks
course of doxycycline is recommended. Chronic Q fever
requires a much more intensive antibiotic regimen consisting of
18–24 months of doxycycline and hydroxychloroquine to resolve
the infection (Kersh, 2013). A deﬁnitive study on the use of pro-
phylactic antibiotic treatment for preventing chronic Q fever has
not been undertaken. Although it is suggested for individuals in
high risk groups, the beneﬁt and duration of treatment have not
been described (Kampschreur et al., 2014).
Given the difﬁculties associated with the treatment of chronic
Q fever, vaccinations have been considered a viable alter-
native for at-risk populations. The utilization of Q-Vax, a
formalin-inactivated whole cell vaccine, in Australia is very
promising demonstrating that effective, vaccine-mediated pro-
tection upward of 5 years against Q fever is possible. (Ackland
et al., 1994). However, Q-Vax does pose issues for individuals
who have been previously exposed to C. burnetii. Individu-
als must undergo serology and skin tests prior to vaccination
and use is restricted to individuals testing negative for both
due to adverse reactions that can occur in previously sensi-
tized individuals (Smadel et al., 1948). More recent development
efforts focused on chemical extraction methods seeking to retain
immunogenicity while trying to dampen the adverse reactions.
Chloroform-methanol extraction of the Henzerling strain was
shown to elicit robust protection but retained the undesirable
adverse reactions (Williams and Cantrell, 1982; Williams et al.,
1986).
PUBLIC HEALTH AND BIODEFENSE CONCERNS
Q fever is a disease of worldwide distribution, but the prevalence
varies widely and signiﬁcant outbreaks do occur on occasion.
For example, a large outbreak occurred in the Netherlands
from 2007 to 2010, with over 4,000 cases being documented
(Fries et al., 1993). Seroepidemiology studies have been con-
ducted around theworld in both humans and agricultural animals.
Table 1 provides a synopsis of key studies with respect to the
seroprevalence of C. burnetii (Marrie et al., 1984; Tellez et al.,
1989; Letaief et al., 1995; Okabayashi et al., 1999; Ko et al.,
2000; Kim et al., 2006; Kilic et al., 2008; McCaughey et al., 2008;
Anderson et al., 2009; Gozalan et al., 2010; Frankel et al., 2011;
Tozer et al., 2011; Esmaeili et al., 2014; Schimmer et al., 2014;
van Wijk et al., 2014). This synopsis sought to focus on those
studies that did not speciﬁcally target at-risk individuals such
as agricultural workers. Most studies found seroprevalence rates
between 3 and 15%. However, a few did suggest rates as high as
20–30%.
Table 1 | Highlights of seroprevalence of Q fever by nation.
Nation Seroprevalence (%)
Australia (Tozer et al., 2011) 5.3a
Australia (Tozer et al., 2011) 5.0a
Canada (Marrie et al., 1984) 4.1/11.8b
Canada (Marrie et al., 1984) 5.0/14.6b
France (Frankel et al., 2011) 2.1
Iran (Esmaeili et al., 2014) 27.8c
Netherlands (vanWijk et al., 2014) 4.4
Netherlands (Schimmer et al., 2014) 72.1d
Northern Ireland (McCaughey et al., 2008) 12.8
South Korea (Kim et al., 2006) 1.5
Spain (rural) (Tellez et al., 1989) 15.4
Spain (urban) (Tellez et al., 1989) 8.8
Taiwan (Ko et al., 2000) 4.2
Tunisia (Letaief et al., 1995) 26
Turkey (Gozalan et al., 2010) 13.5
Turkey (Kilic et al., 2008) 32.3
United States (Anderson et al., 2009) 3.1
Zambia (Okabayashi et al., 1999) 8.2
aComparisons were made between rural (5.3%) and urban (5.0%) populations.
bPercentages reﬂect seropositivity by complement ﬁxation and microimmunoﬂu-
orescence assays.
cPopulation was focused on hunters, farmers, health care workers and others
who were referred by diagnostic laboratories.
dPopulationwas focused on agricultural workers in close associationwith infected
cattle.
The endemnicity of Q fever in Australia has warranted the use
of Q-Vax in vaccination programs. Research into Q fever in Aus-
tralia has been at least in part driven by economic considerations.
Analyses of Q fever from 1991 to 1994 suggested that the costs
associated with the disease were over $1 million Australian dollars
and 1,700 weeks of work annually across Australia (Garner et al.,
1997). While relatively small compared to other diseases, the avail-
ability of a low cost, effective vaccine has provided an economic
beneﬁt.
Some of the highest rates of prevalence for Q fever have been
reported in the Middle East and studies have been conducted in
parallel in both human and animal populations. Recent surveys in
Iran demonstrated high rates of seropositivity in both humans and
sheep. An analysis of sheep showed that 23.7%of animals had anti-
bodies againstC. burnetii (Esmaeili et al., 2013) andparallel studies
in human cohorts demonstrated a seropositivity rate of 27.8%
which correlated with handling of agricultural animals (Esmaeili
et al., 2014). Clinical investigation of febrile illnesses of unknown
origin in Saudi Arabia showed that out of 51 patients who had
febrile illness in the past 4–8 weeks, 35% were seropositive for Q
fever compared to just 4% of the control subjects (Almogren et al.,
2013). Similar analyses in an Iranian cohort demonstrated that 24
and 36% of febrile patients were positive for antibody responses
against phase I and II antigens, respectively (Khalili et al., 2010),
highlighting the endemnicity of Q fever in the Middle East.
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Q fever is a concern for the military due to deployments to
regions where the disease is present at relatively high levels. In an
analysis of a group of U.S. troops that were deployed to an area
of Iraq with known Q fever outbreaks, 7.2% seroconverted during
the deployment (Royal et al., 2013). A larger study of deployed
Warﬁghters followed a cohort of patients that were admitted to
hospitals with fever and other non-speciﬁc symptoms. Out of
909 individuals, 88 were seropositive for Q fever (Anderson et al.,
2011). An outbreak among a smaller group of US Marines that
were deployed to Iraq resulted in 22/38 developing Q fever (Faix
et al., 2008). Similar ﬁndings have been reported by the United
Kingdom military as well. In a 6 months period from May to
October, 2008, 26 cases of HelmandFeverwere identiﬁed inBritish
troops, six of which proved to be Q fever (Bailey et al., 2011). Thus,
while the threat posed by Q fever in the United States is fairly low
from a domestic public health perspective, the recent clinical serol-
ogy data suggest that C. burnetii represents a substantial disease
burden among the deployed military.
Medical countermeasures against Q fever are of interest from
a biodefense perspective. The ease of aerosolization of C. bur-
netii, its low infectious dose, and environmental stability led to its
use in offensive programs prior to the Biological Weapons Con-
vention (Martin and Eitzen, 2007). The United States included
C. burnetii testing in Operation Whitecoat, wherein conscien-
tious objectors were intentionally exposed and monitored for
signs of illness and promptly treated with oxytetracycline (Benen-
son and Tigertt, 1956). An intentional release was also mimicked
by discharging the bacterial aerosol from 3000 feet, or approx-
imately 900 meters (Bellamy and Freedman, 2001). All exposed
individuals were treated with antibiotics and followed for devel-
opment of chronic infection (Tigertt et al., 1961). Testing on
C. burnetii was also ongoing within the Soviet Union’s bio-
logical offense program during 1920s through 1990s (Pittman
et al., 2005). The ubiquitous nature of C. burnetii in the envi-
ronment, as well as its history in offensive programs, have
spurred interest in vaccine programs. To date, vaccine develop-
ment efforts have been largely based in empirical studies, partially
due to the difﬁculties associated with culturing and manipulat-
ing C. burnetii. However, there have been key advances in Q
fever biology that can now greatly facilitate the rational design
of vaccines.
ADVANCES IN Q FEVER BIOLOGY
The ability to generate deﬁned mutants of C. burnetii and grow
the bacterium in cell-free media have provided two major tools
that will continue to facilitate Q fever studies (van Schaik et al.,
2013). The development of an axenic culture media that sup-
port extracellular growth has been crucial to recent advances.
The ﬁrst generation was a complex Coxiella medium that allowed
protein and ATP synthesis upward of 24 h. Metabolism was
retained in a citrate-based buffer supplemented with three com-
plex nutrient sources; neopeptone, fetal bovine serum (FBS), and
RPMI cell medium (Omsland et al., 2008). The second genera-
tion medium, Acidiﬁed Citrate Cysteine Medium demonstrated
bacterial recovery on par with that of Vero cell growth upon the
addition of L-cysteine (Omsland et al., 2009). The current axenic
medium replaced FBS with methyl-β-cyclodextrin. This medium
formulation has been used to successfully culture bacteria directly
from infected animal tissue homogenate. In addition, the doubling
time was decreased, transition between SCV and LCV during sta-
tionary phase has been observed, and by adding a soft agar layer
facilitates the isolation of pure colonies. (Omsland et al., 2011;
Sandoz et al., 2014). Vero cell extract medium was also found to
be permissive to C. burnetii growth, with the bacteria retaining
its antigenicity proﬁle (Singh et al., 2013). Taken together, the
advent of cell-free growth media has facilitated the development
of new genetic tools to be tested in C. burnetii (van Schaik et al.,
2013).
The ability to transform Phase II C. burnetii was demonstrated
by conferring chloramphenicol resistance and mCherry red ﬂuo-
rescent protein by Himar 1 transposon (Beare et al., 2009). Twenty
clonal isolates of Type IV Secretion System substrate mutants
were identiﬁed using the same Himar 1 transposon and trans-
posase approach. Screening of these isolates produced 10 that
were defective in intracellular replication and vacuole forma-
tion, providing insight into the lack of effector redundancy as
observed in Legionella pneumophila and potential novel viru-
lence factors (Weber et al., 2013). Two novel gene deletion systems
were developed in C. burnetii, a Cre-lox mediated recombination
and the loop in-loop out strategy. Using the Cre-lox-mediated
recombination, the structural component of type IVB secretion
system, dotA, was deleted. A double mutant of dotA and dotB
was created with the loop-in/loop-out method in which a sui-
cide plasmid with sacB-mediated counterselection generated an
unmarked mutation (Beare et al., 2012). Furthermore, satura-
tion of the genome by RNA interference was recently used to
create a library of mutants to allow for screening of essential
host pathways for successful C. burnetii infection (McDonough
et al., 2013). A greater understanding of C. burnetii pathogenesis
has, and will continue to, drive investigations into the rational
design of Q fever vaccines. Recent work has suggested that spe-
ciﬁc T cell epitopes may be necessary in the successful design
of a next-generation vaccine against C. burnetii (Xiong et al.,
2014).
PROGRESS TOWARD A Q FEVER VACCINE
As noted above, Q-Vax has been licensed for use in Australia
highlighting an important success by effectively reducing the dis-
ease burden as part of a preventative vaccine program. Q fever
reporting declined by ∼50% from 2002 to 2006 upon the imple-
mentation of a vaccine program targeted toward abattoir workers
and farmers (Gidding et al., 2009). Trials have also been conducted
in at-risk older adults in the Netherlands. Although not as promis-
ing as immunogenicity data in younger cohorts, patients in this
study did demonstrate positive responses by ELISA (46%) and
IFN-γ assays (67%) after 6 months and 1 year (60% for both
assays; Schoffelen et al., 2013). In a related study with a formalin-
inactivated vaccine, 13 out of 16 individuals responded to the
vaccine with positive measures of antibody titers (titer > 1:8)
and IFN-γ responses (>31.1 pg of IFN-γ produced; Kersh et al.,
2013).
Although the above trials have provided much hope in terms
of an effective Q fever vaccine, there are some issues that remain
to be addressed. Protection has clearly been shown in multiple
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efﬁcacy trials and experiments and a meta-analysis of a range of
vaccine campaigns with Henzerling phase I vaccines supported
the conclusion that these vaccines do indeed protect against acute
disease. However, there were differences when comparing individ-
ual studies (O’Neill et al., 2014). Perhaps more importantly, the
various forms of inactivated C. burnetii vaccines require a pre-
sensitivity screening via skin tests and serology. It is important to
note that in a recent vaccine campaign in the Netherlands, 22% of
individuals had to be excluded from the trial due to positive skin
tests and/or serology (Isken et al., 2013). From the perspective of
developing a vaccine for the biological defense of the U.S. military,
the required pre-screening and inability to vaccinate pre-sensitized
individuals poses a logistical challenge that warrants investment
in a next-generation Q fever vaccine.
Since the development of Q-vax and other related whole-cell
inactivated vaccines, the funding for Q fever vaccines, as well
as C. burnetii in general, has been limited. In terms of next-
generation vaccines, the candidate that has moved the furthest
along the pathway toward licensure is a chloroform-methanol
residue vaccine. This candidate was taken forward into a phase
I clinical trial that demonstrated immunogenicity when admin-
istered with a primary vaccination and boost 3–6 months later
(Waag et al., 2008). However, the priming doses did not induce
an increase in C. burnetii-speciﬁc antibody titers and individu-
als with positive titers were excluded from the study (Waag et al.,
2008), thus, it is not clear if the chloroform-methanol residue
would have the same issue as inactivated vaccines with respect
to pre-exposed individuals. The authors of this study discussed
ongoing efforts to characterize this vaccine in individuals who
were positive for reactions to Q fever via a skin test, but nothing
has been published with respect to this to date.
Much of the more recent progress in Q fever has involved a
more basic understanding of factors involved in protection against
infection as opposed to vaccine development. Phase I LPS has
been associated with protection against Q fever in multiple studies
(Zhang et al., 2007; Peng et al., 2012). A Phase I LPS-speciﬁc mon-
oclonal antibody was shown to be protective in a mouse model of
infection (Peng et al., 2012). Utilization of a phage display library
resulted in the discovery of a peptide mimetic that mimics a pro-
tective epitope of Phase I LPS and elicits a protective antibody
response in mice (Peng et al., 2012). There has been somewhat
limited progress toward the identiﬁcation of protein antigens that
may constitute viable antigens to be included in a next-generation
Q fever vaccine. Com1 and Mip surface-exposed proteins have
been shown to be immunogenic in human clinical samples (Vigil
et al., 2011). Immunization of mice with dendritic cells stimulated
with these proteins resulted in increased rates of bacterial clear-
ance, suggesting that the immune response to these proteins may
also contribute to protection against disease (Xiong et al., 2012).
Stimulation of T cells with Com1-pulsed monocyte-derived den-
dritic cells resulted in proliferation and activation of T cells (Wang
et al., 2011).
Additional insights have also been gained into the type of
immune response that may mediate protection against C. bur-
netii. Protection has been associated with antibodies to LPS in
past studies (Zhang et al., 2007; Peng et al., 2012), and it has been
suggested that although antibodies do contribute to protection,
Fc receptors and complement are not required for the mecha-
nism of action (Shannon et al., 2009). There is also a growing
appreciation of the role of T cells in protection against Q fever.
Passive transfer of bone marrow-derived dendritic cells stimu-
lated with C. burnetii antigens resulted in protection against Q
fever. Stimulation with Phase II antigens elicited robust pro-
tection, but Com1 and SecB alone elicited partial protection
that correlated with CD4+ T cell responses (Wei et al., 2011).
Work in SCID mouse models have shown that CD4+ or CD8+
T cells were sufﬁcient to provide protection against disease
(Read et al., 2010). Vaccine studies utilizing formalin-inactivated
C. burnetii have shown that T cells are particularly important
in vaccine-mediated protection against Q fever (Zhang et al.,
2007).
FUTURE INVESTMENTS IN Q FEVER MEDICAL
COUNTERMEASURES
While an effective vaccine is currently in use in Australia, a greater
understanding of Q fever may enable the development of a next-
generation vaccine with fewer reactogenicity issues. Relative to
other Biodefense programs, there can be a much stronger tie
between biodefense and public health indications.
Given the relative lack of information regarding protein anti-
gens of C. burnetii that may constitute viable protective antigens
to be included in vaccine formulation, further investments in
antigen discovery for Q fever are warranted. The number of
clinical Q fever cases around the world has potential to pro-
vide key insights into the discovery phase of a next-generation
vaccine. For example, protein microarrays have been used to
interrogate the antibody responses in Q fever patients, which
covered approximately 93% of the C. burnetii proteome and
have used this tool to study the immune responses to Q fever
infection (Vigil et al., 2011). Clinical immunology studies would
be of continued utility in understanding C. burnetii antigens
that are immunogenic and may contribute to either protective
immune responses or reactogenicity issues associated with vacci-
nations of previously exposed individuals with whole cell Q fever
vaccines.
The ability to tease out protective immune responses versus
those involved in reactogenicity will enable rationally designed
Q fever vaccines that would not require the requisite pre-
screening. In order to develop such a vaccine, the Q fever research
community needs the tools to study the immune response to
C. burnetii. Well-characterized assays will be needed to analyze
the immune responses, most likely both antibody and T cell
responses, to the antigens being included in next-generation vac-
cines. If a Q fever vaccine is to be licensed for use, regardless
of pre-exposure status, care will need to be taken in animal
model experimentation to assess the likelihood of pre-exposure
sensitivity.
Concerted efforts to (1) identify optimal antigens to be included
in a vaccine, (2) develop models pre-exposure sensitivity to Q
fever vaccination, and (3) demonstrate proof-of-concept safety
and efﬁcacy against C. burnetii challenge could provide candidate
countermeasures in the relatively near future. As the community
drives toward late-stage vaccine candidates, there will be opportu-
nities for partnerships between the biodefense, public health, and
Frontiers in Microbiology | Infectious Diseases December 2014 | Volume 5 | Article 726 | 4
Ruiz andWolfe Q fever vaccines
agricultural stakeholders in order to achieve a Q fever vaccine that
is relevant to the needs of the broader community as well as the
Warﬁghter.
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